Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Expression”

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05403242
What this trial is testing

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Who this might be right for
Advanced Gastroesophageal Adenocarcinoma
Chinese PLA General Hospital 42
Not applicableUnknownNCT04288141
What this trial is testing

Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies

Who this might be right for
HER2-positive Breast Cancer
King's College London 40
Early research (Phase 1)Ended earlyNCT02512237
What this trial is testing

A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression

Who this might be right for
Breast NeoplasmsStomach Neoplasms
Zhejiang Medicine Co., Ltd. 9
Testing effectiveness (Phase 2)Study completedNCT00479674
What this trial is testing

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Duke University 41
Not applicableUnknownNCT05169853
What this trial is testing

Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerHER2-positive Breast Cancer
Ain Shams University 80
Early research (Phase 1)Study completedNCT03255070
What this trial is testing

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Who this might be right for
Breast NeoplasmsGastric NeoplasmSolid Tumors
Ambrx, Inc. 106
Not applicableNot Yet RecruitingNCT07670182
What this trial is testing

The Efficacy of Combined Peripheral Blood CTCs and Serum HER2 Detection in Docetaxel-based Treatment for HER2 Low-expression Breast Cancer

Who this might be right for
Patients With Low HER2 Expression (IHC 1+ or IHC 2+/ISH-) and HER2 IHC 0 Advanced Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 100
Testing effectiveness (Phase 2)UnknownNCT06227156
What this trial is testing

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Castration-resistant Prostate Cancer
RemeGen Co., Ltd. 40
Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Very early researchLooking for participantsNCT06822998
What this trial is testing

HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
HighField Biopharmaceuticals Corporation 10
Testing effectiveness (Phase 2)Study completedNCT05412446
What this trial is testing

99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes

Who this might be right for
Breast CancerFemale
Tomsk National Research Medical Center of the Russian Academy of Sciences 30
Testing effectiveness (Phase 2)Looking for participantsNCT06656624
What this trial is testing

Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)

Who this might be right for
Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 190
Testing effectiveness (Phase 2)Looking for participantsNCT05911958
What this trial is testing

SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

Who this might be right for
HER2 Low Breast Carcinoma
Henan Cancer Hospital 66
Not applicableStudy completedNCT01446185
What this trial is testing

Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients

Who this might be right for
Breast Cancer
Genomic Health®, Inc. 100
Early research (Phase 1)Study completedNCT01895491
What this trial is testing

Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer

Who this might be right for
Breast Cancer
Reyon Pharmaceutical Co., Ltd. 9
Testing effectiveness (Phase 2)Ended earlyNCT00636441
What this trial is testing

Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer

Who this might be right for
Early-Stage Breast Cancer
Duke University 56
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07662473
What this trial is testing

The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or Metastatic NSCLC With HER2 Over Expression

Who this might be right for
NSCLC
Hunan Province Tumor Hospital 30
Large-scale testing (Phase 3)Active Not RecruitingNCT05980481
What this trial is testing

RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
RemeGen Co., Ltd. 201
Not applicableStudy completedNCT00898898
What this trial is testing

Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 2,837
Not applicableUnknownNCT05834699
What this trial is testing

HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC

Who this might be right for
Breast Cancer
Beijing 302 Hospital 50
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation